GSK plc (GSK) Ownership
GSK ownership summary
as of October 18, 2026- Institutions
- 17.5% of shares outstanding
- Insiders
- 0.06% of shares outstanding
- Shares outstanding
- 2.00B
- Float
- 1.94B shares available to trade
- Short interest
- 0.74% 14.8M shares short
- Days to cover
- 4.77 short interest up 9.2% vs prior month
- Institutions 17.46%
- Insiders 0.06%
- Other investors 82.48%
GSK top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | FMR Inc | 3.24% | 65.0M | $3.22B | −2.7M (−4.0%) | June 30, 2026 |
| 2 | Dodge & Cox | 2.40% | 48.2M | $2.39B | −10.5M (−17.8%) | June 30, 2026 |
| 3 | Fisher Asset Management, LLC | 1.78% | 35.7M | $1.77B | +1.2M (+3.5%) | June 30, 2026 |
| 4 | PRIMECAP Management Company | 1.26% | 25.2M | $1.25B | −22,470 (−0.1%) | June 30, 2026 |
| 5 | Wellington Management Company LLP | 0.57% | 11.4M | $564.2M | −321,364 (−2.7%) | June 30, 2026 |
| 6 | JTC Employer Solutions Trustee Ltd | 0.43% | 8.6M | $425.4M | −449,402 (−5.0%) | June 30, 2026 |
| 7 | Morgan Stanley - Brokerage Accounts | 0.38% | 7.7M | $379.1M | −3.4M (−30.6%) | June 30, 2026 |
| 8 | Royal Bank of Canada | 0.38% | 7.6M | $375.7M | +82,142 (+1.1%) | June 30, 2026 |
| 9 | T. Rowe Price Associates, Inc. | 0.35% | 6.9M | $342.8M | −399,191 (−5.5%) | June 30, 2026 |
| 10 | Acadian Asset Management LLC | 0.33% | 6.7M | $329.8M | −5.1M (−43.5%) | June 30, 2026 |
| 11 | The Goldman Sachs Group Inc | 0.32% | 6.4M | $315.5M | −3.2M (−33.6%) | June 30, 2026 |
| 12 | State Street Corp | 0.30% | 6.0M | $295.0M | −39,371 (−0.7%) | June 30, 2026 |
| 13 | Mondrian Investment Partners Ltd | 0.24% | 4.9M | $243.1M | −76,563 (−1.5%) | June 30, 2026 |
| 14 | Bank of Montreal | 0.20% | 4.0M | $200.2M | −596,936 (−12.9%) | June 30, 2026 |
| 15 | BMO Capital Markets Corp. | 0.20% | 4.0M | $200.2M | −596,936 (−12.9%) | June 30, 2026 |
| 16 | BlackRock Inc | 0.18% | 3.6M | $179.2M | +69,390 (+2.0%) | June 30, 2026 |
| 17 | Grantham, Mayo, Van Otterloo & Co., LLC | 0.18% | 3.6M | $178.2M | +76,955 (+2.2%) | June 30, 2026 |
| 18 | Hotchkis & Wiley Capital Management LLC | 0.17% | 3.4M | $169.0M | −68,480 (−2.0%) | June 30, 2026 |
| 19 | Equity Investment Corp | 0.16% | 3.3M | $161.9M | +48,730 (+1.5%) | June 30, 2026 |
| 20 | UBS Group AG | 0.14% | 2.8M | $138.9M | +721,970 (+34.6%) | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 6 holders added 2.2M shares and 14 cut 27.5M.
GSK top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Dodge & Cox Stock I | 1.68% | 33.8M | $1.67B | −9.2M (−21.4%) | June 30, 2026 |
| 2 | Vanguard PRIMECAP Inv | 0.91% | 18.2M | $899.7M | +25,000 (+0.1%) | June 30, 2026 |
| 3 | Vanguard Wellington Inv | 0.48% | 9.7M | $478.4M | −194,803 (−2.0%) | June 30, 2026 |
| 4 | Strategic Advisers Fidelity US TtlStk | 0.40% | 8.0M | $397.0M | +41,100 (+0.5%) | August 31, 2026 |
| 5 | Fidelity Series Large Cap Stock | 0.23% | 4.6M | $226.7M | — | August 31, 2026 |
| 6 | Fidelity Series Value Discovery | 0.20% | 4.0M | $195.7M | −184,200 (−4.5%) | August 31, 2026 |
| 7 | Vanguard PRIMECAP Core Inv | 0.18% | 3.5M | $175.7M | +5,000 (+0.1%) | June 30, 2026 |
| 8 | Dodge & Cox Balanced I | 0.17% | 3.4M | $170.7M | −788,300 (−18.6%) | June 30, 2026 |
| 9 | Fidelity Growth & Income | 0.17% | 3.4M | $170.3M | — | August 31, 2026 |
| 10 | Fidelity Equity Dividend Income | 0.13% | 2.7M | $133.5M | — | August 31, 2026 |
| 11 | T. Rowe Price International Value Eq | 0.13% | 2.6M | $130.5M | −4,113 (−0.2%) | August 31, 2026 |
| 12 | Fidelity Select Pharmaceuticals Port | 0.13% | 2.6M | $127.6M | — | August 31, 2026 |
| 13 | Fidelity Large Cap Stock | 0.09% | 1.7M | $84.6M | — | August 31, 2026 |
| 14 | Vanguard Windsor II Inv | 0.08% | 1.6M | $79.1M | — | June 30, 2026 |
| 15 | Bridge Builder Large Cap Value | 0.08% | 1.5M | $75.0M | — | September 30, 2026 |
| 16 | Avantis International Equity ETF | 0.07% | 1.4M | $71.0M | +3,120 (+0.2%) | September 30, 2026 |
| 17 | BGF World Healthscience A2 | 0.06% | 1.2M | $59.0M | — | June 30, 2026 |
| 18 | Fidelity Enhanced International ETF | 0.06% | 1.1M | $55.5M | +3,112 (+0.3%) | September 30, 2026 |
| 19 | PRIMECAP Odyssey Stock | 0.06% | 1.1M | $55.3M | — | June 30, 2026 |
| 20 | Fidelity Advisor Capital Development O | 0.05% | 1.1M | $53.3M | — | August 31, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
GSK insider transactions
latest 1| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2025-12-11 | Plc Gsk | Buy | $19.00 | 1,470,000 | $27.9M |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
GSK shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns GSK
Institutional investors own 17.5% of GSK's shares and insiders 0.06%. The largest holder is FMR Inc with 3.24% of the shares (65.0M), as of June 30, 2026. Among the top 20 institutions, 6 added shares and 14 reduced their stake in the latest filings. Short interest is 0.74% of the float, or 4.77 days of average trading volume. The share count rose 5.1% since 2014.
Related: GSK analyst forecast, GSK dividend history. See the GSK stock overview for the latest quote and news.
GSK ownership FAQ
Who owns the most GSK stock?
The largest shareholders of GSK are FMR Inc (3.24%), Dodge & Cox (2.40%), Fisher Asset Management, LLC (1.78%), PRIMECAP Management Company (1.26%), Wellington Management Company LLP (0.57%).
What percentage of GSK is owned by institutions?
Institutions hold 17.5% of GSK's shares outstanding; insiders hold 0.06%.
Which funds own GSK?
The largest fund holders of GSK are Dodge & Cox Stock I (1.68%), Vanguard PRIMECAP Inv (0.91%), Vanguard Wellington Inv (0.48%), Strategic Advisers Fidelity US TtlStk (0.40%), Fidelity Series Large Cap Stock (0.23%).
What is GSK's short interest?
14.8M shares of GSK were sold short, 0.74% of the float; at the average daily volume it would take 4.77 days to cover.
Are insiders buying or selling GSK?
Of the latest 1 reported insider transactions in GSK (since December 11, 2025), 1 were purchases and 0 were sales.
How many shares of GSK are outstanding?
GSK has 2.00B shares outstanding, of which 1.94B are in the public float.